Company Overview

About Aridis

 

Aridis Pharmaceuticals, Inc. is a privately held biopharmaceutical company focused on the development of novel, differentiated therapies for infectious diseases. Complementing the product pipeline is a disruptive platform technology to discover rare, potent human monoclonal antibodies from patients. Our scientists and leadership team have a proven track record of innovation and successful drug development of therapeutic candidates from early discovery to commercial implementation.

 

The Company’s anti-infective product portfolio includes three clinical stage monoclonal antibodies (mAb) and three additional preclinical anti-infective drug candidates. This suite of anti-infective monoclonal antibodies is highly differentiated from conventional antibiotics, effective against all antibiotic resistant strains which the mAbs are directed against, and offers opportunities to profoundly impact current approaches to infection control.